Anavex Life Sciences Corp (AVXL)

[JB3729]

IR has already told us what to expect. I added the statement in red -


Pazzo1212 Thursday, 03/17/16 06:39:36 PM
Re: blu_1 post# 57177
Post # of 57652

Here's the email I received from IR yesterday:

Thank you for your email and support of Anavex Life Sciences Corp. (Nasdaq: AVXL).

In the AAT presentation (http://www.anavex.com/files/2016-03-12_AAT_Anavex_Presentation_2016.pdf), slide 24 demonstrates encouraging functional measurement of interim 12-week data, which was originally presented at CTAD. (Dr.Missling reported 12 week data before the end of the qtr)

Complete longitudinal data for the 12-week time point of PART B will be provided once this data becomes available. This is not yet available to the company. As stated in the third bullet point on slide 26 of the AAT presentation, please be assured that it will be issued once available, however we are unable to provide guidance on the timeline. The details relating to pharmacokinetics and pharmacodynamics are being fully analyzed so that there can be no doubt as to the cause-effect relationship of the 12-week efficacy data and this must be completed before it can be released.

The company is excited about the data received to date and by the request for an additional two-year extension from patients and caregivers, as announced in a press release March 10, 2016.

Please do not hesitate to contact our office if we can be of further assistance.

On behalf of Anavex Life Sciences Corp.,

Investor Relations
Toll Free (North America): 1 [phone]
Outside North America: [phone]
Fax: [phone]
[e-mail]